Kala Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Mar 2026
Net Income -$19.7MTTM through 31 Mar 2026
Free Cash Flow -$26.1MTTM through 31 Mar 2026
Margins
| Current |
|---|
Returns
-13.4%ROE
-94.9%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio7.91x
Net Debt-$8.8Mnet cash position
Cash & Equivalents$8.8M
Quality Metrics
Earnings-Beat Rate75.0%
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.